JPRN-UMIN000013274已完成2 期
Efficacy and feasibility study of docetaxel + capecitabine followed by FEC neoadjuvant therapy for hormone receptor positive and HER2 negative breast cancer - docetaxel + capecitabine followed by FEC neoadjuvant therapy for triple negative breast cancer
Department of Surgical Oncology, Osaka City University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2014年2月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1 HER2 positive 2 Pregnant or breast feeding 3 Severe infectious disease 4 Active another cancer 5 Hypersensitivity for 5FU, docetaxel or polysolvate 6 Investigator's judgement of inappropriateness for perticipation
研究者
相似试验
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
招募中
1 期
Investigation of therapeutic efficacy of docetaxel, cisplatin and S1 (DCS) chemotherapy for advanced or recurrent gastric cancerAdvanced/Recurrent Gastric cancerJPRN-UMIN000019972Teikyo University Chiba Medical Center40
招募中
不适用
Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.gastric cancerJPRN-UMIN000005984Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)20
已完成
2 期
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601)Gastric cancerJPRN-UMIN000001119Department of Gastroenterology, Kitasato University School of Medicine45
已完成
不适用
A feasibility study of docetaxel + cisplatin + capecitabine (DCX) therapy for unresectable advanced gastric cancerGastric cancerJPRN-UMIN000006009Department of Gastroenterology, Nagoya University Graduate School of Medicine6